

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO



No. 12-055349- -00003-0000

Fecha: 2012-05-11 16:41:22 Dep. 2020 DIR.NUEVASCR
Tra. 11 PATENTEIYII Eve: 378 FASENACIONALI
Act. 444 RESPUESTAREQUE Folios: 2

Act. 444 RESPUESTAREQUE Folios: 25

Señor

División de Nuevas Creaciones

E. S. D.

Ref: EXPEDIENTE N° 12-055349

Solicitud de patente a nombre de

ALLERGAN, INC

Me refiero al Oficio N° 6335 notificado en el asunto de la referencia y al respecto manifiesto que las Reivindicaciones de la fase nacional difieren de las publicadas en la fase internacional debido a que en el formulario de solicitud se incurrió en una omisión al señalar como WO2011/028955, cuando debió ser:


WO 2011/028995 A1

Adjunto copia de dicha publicación que ha sido revisada y corresponde a lo presentado inicialmente en esta solicitud.

Por lo que respecta a la copia del documento en que consta la cesión del derecho a la patente observo que los documentos que acreditan la cesión fueron presentados con mi memorial de fecha 17 de Abril del año en curso.

Como el expediente está formalmente completo, pido se ordene la publicación del extracto.

Atentamente,


JERONIMO CASTILLO BONILLA
C.C. 79.462.057 Bogotá
T.P. 104167 C.S.Judicatura

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 March 2011 (10.03.2011)

(10) International Publication Number
WO 2011/028995 A1

PCT

(51) International Patent Classification:

C07D 401/04 (2006.01) A61K 31/4436 (2006.01)
C07D 401/14 (2006.01) A61K 31/4439 (2006.01)
C07D 405/14 (2006.01) A61P 35/00 (2006.01)
C07D 409/04 (2006.01) A61P 27/02 (2006.01)
C07D 409/14 (2006.01) A61P 29/00 (2006.01)
A61K 31/443 (2006.01) A61P 3/10 (2006.01)

(21) International Application Number:

PCT/US2010/047800

(22) International Filing Date:

3 September 2010 (03.09.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/239,603 3 September 2009 (03.09.2009) US
61/306,616 22 February 2010 (22.02.2010) US
61/356,699 21 June 2010 (21.06.2010) US
61/360,531 1 July 2010 (01.07.2010) US

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): AL-
LERGAN, INC. [US/US]; 2525 Dupont Drive, Irvine,
California 92612 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): GUO, Xiaoling [US/
US]; 2912 Canto De Los Ciervo, San Clemente, Califor-
nia 92673 (US). ZHU, Zhen [CN/US]; 12 Banyan,
Foothill Ranch, California 92610 (US).

(74) Agents: WURST, John et al.; Allergan, Inc., 2525
Dupont Drive, Irvine, California 92612 (US).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: COMPOUNDS AS TYROSINE KINASE MODULATORS



(57) Abstract: The present invention is directed to novel compounds of Formula (I). The compounds of the present invention are potent tyrosine kinase modulators, and are suitable for the treatment and prevention of diseases and conditions related to abnormal activities of tyrosine kinase receptors.

WO 2011/028995 A1